Company Description
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally.
It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals’ post-stroke.
The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors.
The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024.
Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
| Country | Israel |
| Founded | 2001 |
| IPO Date | Sep 12, 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 80 |
| CEO | William Grant |
Contact Details
Address: 3 Hatnufa Street, Floor 6 Yokneam Illit, 2069203 Israel | |
| Phone | 972 4 959 0123 |
| Website | golifeward.com |
Stock Details
| Ticker Symbol | LFWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001607962 |
| ISIN Number | IL0011331076 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| William Mark Grant | President, Co-Chief Executive Officer and Director |
| Lawrence J. Jasinski BS, MBA | Co-Chief Executive Officer and Director |
| Miri Pariente | Vice President of Operations, Regulatory and Quality |
| Jeannine Lynch | Vice President of Market Access and Strategy |
| Almog Adar | Vice President of Finance and Chief Accounting Officer |
| Judy Kula | Vice President of Customer Service, Human Resources and Business Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2025 | SCHEDULE 13G | Filing |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 26, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 26, 2025 | 424B4 | Prospectus |
| Jun 25, 2025 | EFFECT | Notice of Effectiveness |
| Jun 25, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 20, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 16, 2025 | 8-K | Current Report |
| Jun 16, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 3, 2025 | 8-K | Current Report |